Trending menu:
Oncology
-
17 January 2020 News
BioTheryX initiates patient dosing in trial of BTX-A51 for AML
BioTheryX has initiated patient dosing in a Phase I study of BTX-A51 for the treatment of relapsed/refractory acute myeloid leukaemia (AML).
-
16 January 2020 News
BerGenBio reports positive results from first stage of NSCLC study
Norwegian biopharmaceutical company BerGenBio has reported positive results from the first stage of a Phase II trial (BGBC008) assessing the efficacy of a combination in treating non-small cell lung cancer...
-
16 January 2020 News
Tolero Pharmaceuticals doses first patient in Phase II Zella 202 study
Tolero Pharmaceuticals has dosed the first patient in a Phase II Zella 202 study of investigational agent alvocidib.
-
14 January 2020 News
Genome & Company, Merck and Pfizer sign clinical trial agreement
Genome & Company, Merck and Pfizer have signed a clinical trial collaboration and supply agreement to evaluate GEN-001 therapy in oncology indications as part of Phase I/Ib clinical trial.
-
13 January 2020 News
Iovance and Cellectis agree research and license collaboration
US-based T cell-based cancer immunotherapies developer Iovance Biotherapeutics and clinical-stage biopharmaceutical firm Cellectis have signed a research collaboration and exclusive worldwide license agreement.
-
3 January 2020 Analysis
2019 top news stories
Athersys reports positive data from MultiStem cell therapy trial and CRISPR and Vertex treat first patient in gene-editing therapy trial. Clinicaltrialsarena.com wraps up the key headlines from 2019.
-
23 December 2019 Comment
Benchmarking Phase II industry-sponsored colorectal cancer trials
Colorectal cancer is the second most common cause of cancer deaths in men and women combined in the US.
-
20 December 2019 News
Exelixis partners with Roche to trial cancer combination therapy
Biotechnology company Exelixis has entered a clinical collaboration agreement with Roche to conduct three Phase III clinical trials of combination therapy to treat cancer.
-
18 December 2019 News
TrialJectory raises funds to expand patient access to clinical trials
TrialJectory has raised $2.7m through a seed financing round to expand access to advanced treatments using artificial intelligence (AI) for patients with cancer.
-
18 December 2019 Comment
Early phase II data cuts suggest Aprea’s APR-246 will be a game-changer for TP53 mutant MDS
Aprea Therapeutics presented results from trials in patients with acute myeloid leukaemia.